This particular drug is released from its complex into the bloodstream,
and the amphotericin B that remains in plasma is more than 90% bound to
proteins, largely b-lipoprotein. Approximately 2 to 5% of each dose
appears in the urine when patients are on daily therapy. Elimination
of the drug appears to be unchanged. Hepatic or biliary disease has
no known effect on metabolism of the drug in human beings. Because
of the colossal size of amphotericin B, the human body has no good idea
of what to do with the compound and for that reason the parent compound
is hardly metabolized into more polar forms.